Why the study?
Cancer treatment associated cardiotoxicity (CTAC) increasingly burdens cancer survivors, but published data on biomarkers are inconsistent and recommendations remain mostly based on expert consensus.
Can cardiac biomarkers (cTn and BNP) integrated with cardiac imaging predict and detect subclinical cardiotoxicity in cancer patients undergoing antineoplastic treatment?
Can cardiac biomarkers (cTn and BNP) integrated with cardiac imaging predict and detect subclinical cardiotoxicity in cancer patients undergoing antineoplastic treatment?
Cardiac biomarkers such as troponin and BNP, especially when integrated with cardiac imaging, are valuable tools for the early detection of cancer treatment-associated cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Cardiac biomarkers may aid early CTAC detection in survivors; leaves open prospective validation before routine use.
PURPOSE OF THE REVIEW: As the number of cancer survivors increases due to early screening and modern (antineoplastic) treatments, cancer treatment associated cardiotoxicity (CTAC) is becoming an increasing health burden that affects survival and quality of life among cancer survivors. Thus, clinicians need to identify adverse events early, in an effort to take suitable measures before the occurrence of permanent or irreversible cardiac dysfunction. RECENT FINDINGS: Cardiac troponin (cTn) and B-type natriuretic peptide (BNP) have been proven to detect subclinical cardiotoxicity during antineoplastic treatment. As such, these cardio-specific biomarkers could predict which patients are at risk of developing CTAC even before the start of therapy. Nevertheless, there are inconsistent data from published studies, and the recommendations regarding the use of these biomarkers and their validity are mostly based on expert consensus opinion. In this review, we summarize available literature that evaluates biomarkers of CTAC, and we encourage strategies that integrate circulating biomarkers and cardiac imaging in identifying cancer patients that are at high risk.
No takes yet. Share an insight, caveat, or question.
Bračun et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: